Abbott’s Eterna spinal cord stimulation system given FDA approval
pharmafile | December 20, 2022 | News story | Medical Communications |
US-based Abbott Laboratories has announced that their Eterna spinal cord stimulation (SCS) system has been given approval by the FDA. The device is used for the treatment of chronic pain.
The Eterna SCS system is an implantable, rechargeable system which uses Abbott’s low-dose BurstDR stimulation: SCS waveform technology which mimics the brain’s natural pain relief firing patterns. Abbott’s said that BurstDR has shown 23% more pain reduction compared to traditional waveform technology approaches.
The device was developed based on extensive studies conducted with patients, physicians and caregivers to understand what needs were being unmet by current treatment options for chronic pain. Feedback showed that smaller implants with a reduced need to charge were preferred.
Eterna is currently the smallest implantable and rechargeable system on the market for this indication, and only needs to be charged less than five times a year under normal use; this is said to be the lowest recharge burden of available SCS systems.
It also communicates with the patient via an app, which displays real-time battery life and charging status updates.
Pedro Malha, vice president of Abbott’s neuromodulation business, stated: “At Abbott, we deliver products and solutions with the goal of simplifying healthcare, improving clinical outcomes and providing people suffering from chronic pain with the best experience possible. As we progress on this commitment, Eterna is the next major leap forward. Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimised recharging experience – all key features when selecting the best overall system.”